Marijuana as Medicine: Can We See Past the Smoke?

Igor Grant, M.D.
Director, Center for Medicinal Cannabis Research
www.cmcr.ucsd.edu
University of California San Diego
Marijuana Compounds

+ 80 cannabinoids

Isolation, structure and partial synthesis of an active constituent of hashish.
Cannabis: not a new medicine
Main Events that Reawakened Interest in Medicinal Cannabis in the 1990s

- Persistent anecdotal reports of benefits
- Political shifts favoring medicinal access (in USA 23 states now provide for some measure of access)
- Discovery of the endocannabinoid system
  - CB1 and CB2 receptors
  - 2-arachidonoylglycerol (2-AG: Sugiura, et al., Mechoulam et al., 1995), and other signaling molecules
  - Development of synthetic molecules: agonists, partial agonists, antagonists, and other modifiers (e.g., inhibitors of fatty acid amide hydrolase (FAAH). FAAH breaks down anandamide)
Distribution of CB1 Receptors

Green shading indicates distribution of cannabinoid receptors in the body

- CNS
- Intestine
- Liver
Distribution of CB1 Receptors

cerebral cortex
decision making, cognition, & emotional behavior

caudate nucleus
learning & memory system

putamen
regulate movements & influence various types of learning

globus pallidus
regulate voluntary movements

amygdala
responsible for anxiety & stress, emotion & fear, pain

hypothalamus
body temperature, feeding, neuroendocrine function

hippocampus
memory & learning

substantia nigra
important role in reward, addiction, & movement

cerebellum
motor control & coordination

dorsal vagal complex
emesis
The endogenous cannabinoids

- Anandamide
- Virodhamine
- N-arachidonoyldopamine
- 2-Arachidonoylglycerol
- Noladin ether

“Circuit Breaker” Function of CB Receptors

Neurotransmitter (eg., glutamate) action on post synaptic cells triggers them to release endocannabinoids (EC) that act on presynaptic CB receptors to regulate neurotransmission. The EC are then inactivated by FAAH or MGL*

* FAAH = fatty acid amide hydrolase     MGL = monoglyceride lipase  (Courtesy D. Piomelli, UCI)
University of California Center for Medicinal Cannabis Research (CMCR)

Igor Grant, M.D.
Director

J. Hampton Atkinson, MD & Tom Marcotte, PhD, Co-Directors
Barth Wilsey, MD, Ron Ellis, MD, PhD, Mark Wallace, MD, Robert Fitzgerald, PhD, Investigators; Ben Gouaux and Jennifer Marquie Beck, Senior Staff

www.cmcr.ucsd.edu
California Events Leading To CMCR

November 1996: California Prop 215 passes: Compassionate Use Act


August 2000: Center for Medicinal Cannabis Research established at the University of California.

September 2003: Amendment to Medical Marijuana Research Act of 1999, sunset restrictions removed. (SB 295)
Because Cannabis Is a Schedule 1 Drug, and the Only Legal Source Is the Federal Government, Medical Studies Are Challenging

CMCR Review

SRB Approval

Revisions

State of California Review

RAPC

Revisions

 Revised Approved Proposals

DHHS

NIDA

DHHS Review

FDA

DEA HQ

DEA Local

FDA Review

IND#

DEA Review

Revision

Inspection

Order Product

Approval

Begin Studies

CMCR = UCSD Center for Medicinal Cannabis Research; DEA = Drug Enforcement Administration; DHHS = Department of Health & Human Services; FDA = Food and Drug Administration; HQ = headquarters; IND = investigational new drug; NIDA = National Institute on Drug Abuse; RAPC = Research Advisory Panel of California; SRB = scientific review board.

Time from submission of CMCR-approved study to state and federal regulators to study initiation was ~1 year (range, 6-18 months).
Study Locations

UC-Davis
UCSF
San Mateo
UCLA
UC-Irvine
UCSD
CMCR Abrams et al study: Cannabis reduces HIV Neuropathic Pain

Placebo controlled double blind randomized trial of 4% THC containing vs 0% THC MJ cigarettes administered 3x/day for 5 days.

<table>
<thead>
<tr>
<th>SITE</th>
<th>DISORDER</th>
<th>DESIGN</th>
<th>N</th>
<th>DOSE (% THC)</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>UCSD Mark Wallace</td>
<td>Healthy Volunteers (Experimentally-Induced Pain)</td>
<td>Crossover RCT</td>
<td>15</td>
<td>0%, 2%, 4%, 8%</td>
<td>+</td>
</tr>
<tr>
<td>UCSF Donald Abrams</td>
<td>HIV Neuropathy, Experimental Pain</td>
<td>Parallel Groups RCT</td>
<td>50</td>
<td>0%, 3.5%</td>
<td>+</td>
</tr>
<tr>
<td>UCSD Ronald Ellis</td>
<td>HIV Neuropathy</td>
<td>Crossover RCT</td>
<td>28</td>
<td>0%, 1-8%</td>
<td>+</td>
</tr>
<tr>
<td>UCD Barth Wilsey</td>
<td>Neuropathic Pain, Experimental Pain</td>
<td>Crossover RCT</td>
<td>33</td>
<td>0%, 3.5%, 7%</td>
<td>+</td>
</tr>
<tr>
<td>UCD Barth Wilsey</td>
<td>Neuropathic Pain</td>
<td>Crossover RCT</td>
<td>39</td>
<td>0%, 1.29%, 3.53% (Vaporized)</td>
<td>+</td>
</tr>
<tr>
<td>UCSD Jody Corey-Bloom</td>
<td>MS Spasticity</td>
<td>Crossover RCT</td>
<td>30</td>
<td>0%, 4%</td>
<td>+</td>
</tr>
<tr>
<td>UCSD Mark Wallace</td>
<td>Diabetic Neuropathy</td>
<td>Crossover RCT</td>
<td>16</td>
<td>0%, 2%, 4%, 7%</td>
<td>+</td>
</tr>
</tbody>
</table>
How effective is cannabis relative to other pain medications? Number-Needed-to-Treat

- Number-Needed-to-Treat (NNT) = 1/Proportion improved in experimental condition – Proportion improved on placebo

- Ex: If 30% reduction in pain intensity = “Improved” and 60% “improve” in the experimental condition, while 30% “improve” in the placebo condition, then 0.60 – 0.30 = 0.30 and

NNT = 1/.30 = 3.3
Common Analgesics for Neuropathic Pain

<table>
<thead>
<tr>
<th>Drug</th>
<th>Number Needed to Treat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tricyclics</td>
<td>2.2</td>
</tr>
<tr>
<td>Cannabis</td>
<td>3.6</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>3.7</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>5.4</td>
</tr>
<tr>
<td>SSRIs</td>
<td>6.7</td>
</tr>
</tbody>
</table>

*Number Needed to Treat to achieve a 30% reduction in pain.
Summary of CMCR Studies on Smoked Cannabis

- Data from CMCR placebo controlled, limited scale studies of smoked cannabis indicate positive response in neuropathic pain with effect sizes similar to other agents
- One CMCR study also found smoked cannabis reduced spasticity in MS patients
- Side effects were generally mild, with commonest being subjective high, fatigue, and tachycardia
- Neurocognitive testing revealed small reversible decrements during active treatment; comparable to effects of benzodiazepines, and antispasm, antiepileptic drugs for neuropathic pain and spasm
- Other side effects were sedation, dizziness, cough, throat irritation; all reversible and none necessitating discontinuation
Evidence for Therapeutic Benefits of Cannabis

- **Substantial/conclusive evidence of cannabinoid efficacy in:**
  - chronic pain
  - Spasticity of multiple sclerosis
  - Control of nausea

- **Moderate evidence of cannabinoid efficacy in:**
  - Improving sleep in those with chronic medical conditions, e.g., chronic pain, fibromyalgia etc.

- **Limited evidence of cannabinoid efficacy in**
  - Treatment of certain anxiety disorders and PTSD
  - Promoting appetite and weight gain

- **No or insufficient evidence of cannabinoid efficacy in**
  - Treatment of cancers, irritable bowel syndrome, epilepsy, movement disorders due to Huntington Disease or Parkinson Disease, Schizophrenia

Although it may be effective, smoked marijuana as medicine presents challenges

- Safety of combustible material in clinical setting
- Second hand smoke as an irritant, possibly health hazard
- Efficiency and tolerability in smoking naïve
- Availability of cigarettes with standardized dose
- Conflict with anti drug laws
- Possibility of misuse and diversion
- Difficulty in conducting clinical trials on Schedule I substance whose legal availability is limited
Plasma THC Levels – Smoked vs. Oral

Mean plasma concentrations of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC (THC-COOH) following administration smoked cannabis vs. oral dronabinol.

Devices for Marijuana Vaporization

- E-cigarettes
- Volcano®

Courtesy David Gorelick, MD
Alternative Delivery Systems: “Volcano”

- Cannabis heated to 180°C
- Below the point of combustion (230°C)
- Releases cannabinoids as vapor into balloon
- Inhaled via mouthpiece attached to balloon

STORZ & BICKEL GMBH & CO. KG
CMCR Wilsey vaporizer study: Low dose THC containing cannabis reduces neuropathic pain

Placebo controlled randomized crossover study of 39 patients with neuropathic pain of mixed etiology treated 2x/d. THC conc. = 0%; 1.3%; 3.5%

Nabiximols (Sativex®) oral mucosal spray

- Pump action oral mucosal spray
- Delivers 0.1 ml per spray of solution containing 25 mg/ml THC and 25 mg/ml CBD
- Derived from botanical sources, thus contains other cannabinoids and non-cannabinoids (e.g., flavonoids; terpenes)

Image courtesy G. Guy, GW Pharmaceuticals
Reduction of global neuropathic pain NRS scores in the two groups during the trial. Weekly mean pain scores were obtained from pain diaries.

Current or potential cannabinoid modulators that may be administered orally

- **Agonists**
  - Cannabis itself
  - Synthetic THC (Dronabinol [Marinol] & analogs): Nabilone [Cesamet]; selective CB1 or CB2 agonists

- **Antagonists, partial agonists**
  - (Rimonabant, Taranabant, etc)

- **Modifiers of endocannabinoid metabolism**
  - Fatty Acid Amide Hydrolase (FAAH) inhibitors; possibly monoglyceride lipase (MGL) inhibitors
Other Cannabinoids: Cannabidiol

Terpene phenolic heterocyclic structures of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

*Not active at CB1 or CB2

No psychoactive effect

Cannabidiol - CBD

- Natural component of the Cannabis plant
- Constitutes up to 40% of marijuana extracts
- Devoid of typical psychological effects of THC
- Suggested applications as:
  - Anti-inflammatory
  - Analgesic
  - Anti-emetic
  - Hypnotic and sedative
  - Antipsychotic
  - Anticonvulsive
  - Neuro-protective
  - Anxiolytic
  - Others

- Antagonism of THC when both contents are administered concomitantly? FAAH inhibition?

Slide information courtesy of Dr. José Alexandre de Souza Crippa, Department of Neurosciences and Behavior, Ribeirão Preto Medical School, University of São Paulo, Brazil
Possible mechanisms of action of CBD

» Does not activate CB1 or CB2

» Desensitizes transient receptor potential channels, e.g., TRPV1: anti-nociceptive to inflammatory pain?

» Blocks GPR55, which may also play a role in neuropathic and inflammatory pain

» Enhances glycine receptor activity: anticonvulsant?

» Inhibits FAAH: increasing availability of anandamide?

» Enhances 5HT1A receptor: anxiolytic effect?

» Modulates cytochrome P4502C metabolism of THC to more psychoactive 11-OH THC?
### Cannabidiol: Seizure Reduction in Epilepsy

<table>
<thead>
<tr>
<th>STUDY</th>
<th>MODEL</th>
<th>EFFECT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Human</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Devinsky et al., 2015</td>
<td>N=137 children Dravet or Lennox Gastaud. Epidiolex, a CBD extract</td>
<td>+</td>
</tr>
<tr>
<td>Porter, et al. (2013)</td>
<td>N=19, children with treatment resistant epilepsy, survey results</td>
<td>+</td>
</tr>
<tr>
<td>Trembly, et al. (1990)</td>
<td>N=12, 300mg cannabidiol/placebo</td>
<td>-</td>
</tr>
<tr>
<td>Ames, et al. (1985)</td>
<td>N=12, uncontrolled seizures, 200-300mg cannabidiol/placebo daily</td>
<td>-</td>
</tr>
<tr>
<td>Cunha, et al. (1980)</td>
<td>N=15, temporal lobe epilepsy, 200-300mg cannabidiol/placebo daily</td>
<td>+</td>
</tr>
<tr>
<td>Mechoulam, et al. (1978)</td>
<td>N=9, temporal lobe epilepsy, 200mg cannabidiol/placebo</td>
<td>+</td>
</tr>
<tr>
<td><strong>Pre-Clinical</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consroe, et al (1982)</td>
<td>Seizures induced by strychnine sulphate</td>
<td>-</td>
</tr>
</tbody>
</table>

Cannabidiol (CBD) Significantly Reduces Convulsive Seizure Frequency in Lennox-Gastaut Syndrome (LGS)

- 120 children/young adults
- 20 mg/kg CBD
- 14-week treatment period
- % with > 50% reduction in frequency (CBD – 43%; Placebo - 27%)
- AEs (diarrhea, vomiting, fatigue, etc.)

Devinsky et al., 2017 (NEJM)
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

Slide information courtesy of Dr. José Alexandre de Souza Crippa, Department of Neurosciences and Behavior, Ribeirão Preto Medical School, University of São Paulo, Brazil.
CBD Improves Positive and Negative Symptoms of Schizophrenia

42 cases randomized to receive 800 mg/d CBD or amisulpride

PANSS = Positive and Negative Syndrome Scale.

Data show predicted means and side effects. Statistical significance is calculated between groups and versus baseline, that is, 0 (*CBD, #AMI; \( P \leq 0.001 \); ***/#P \leq 0.05).
Compared to Atypical Antipsychotic Amisulpride, CBD Does Not Worsen Extrapyramidal Symptoms, and Is Not Associated with Weight Gain or Elevated Prolactin

Extrapyramidal Symptom Scale (EPS)

Weight Gain

Prolactin

Data show predicted means and side effects. Statistical significance is calculated between groups (††P ≤ 0.01, †††P ≤ 0.001 and versus baseline, that is, 0 (*CBD, #AMI; ##P ≤ 0.01; ###P ≤ 0.05; */#P ≤ 0.001)).

Summary of current status of Medicinal Cannabis/Cannabinoid Modulators

- Smoked/vaporized cannabis, and extracts containing THC/CBD mix probably efficacious in neuropathic pain and spasticity from MS
- Possible efficacy in sleep disorders treatment
- Synthetic THC-like molecules efficacious in appetite stimulation and control of nausea
- Potential utility of other synthetic CB1 agonists not yet established
- CB1 antagonists, partial agonists may be useful in appetite suppression, but adverse psychiatric effects have been problematic
- Cannabidiol showing initial promise in treatment of anxiety, psychosis, and intractable epilepsy (eg., Dravet; Lennox Gastaut Syndromes: FDA approves Epidiolex 6/25/18)
- FAAH inhibitors promising in animal models of chronic pain
- Anti-inflammatory actions of cannabinoids deserve further exploration
Medical Cannabis: Potential Public Health Benefits

- Decreased opioid analgesic overdose deaths
  » Mean 25% decrease in states with medical cannabis
- Decreased opioid analgesic use
  » 47% reduction in daily opioid dose
- Decreased obesity
  » Associated with 2-6% decreased probability of obesity
- Decreased alcohol use
  » In medicinal vs recreational users

Courtesy David Gorelick, MD

Medical Cannabis: Potential Public Health Harms

- Increased cannabis use
  » Found in some, but not all, epidemiological analyses
- Increased incidence of cannabis use disorders
  » Small increase in recent epidemiological analysis (Hasin et al., JAMA Psychiatry, 2017)
- Increased alcohol use
  » Some evidence for both increased and decreased use (substitution)
- Increased cannabis-associated motor vehicle accidents?
  » Data inconsistent, and causal links hard to establish
- Increased unintended cannabis overdoses
  » in Colorado, especially among children (e.g., Davis et al., JAMA Psychiatry, 2017)
- Increased crime around cannabis dispensaries
  » Only in immediate vicinity (Long Beach, CA study)

Courtesy David Gorelick, MD
How do we move forward? In most countries, including the USA, it isn’t that easy

- We need to separate out discourse on medicinal cannabis from that of broader social policy on recreational use [as we have done with other abusable drugs]
- We need both proof of principle and larger scale clinical trials on cannabis, administered via several routes, and specific constituents, plus their combinations. Consider effects of age, sex, comorbidities, other medications
- Tax dollars collected from cannabis sales can support such studies, which should also focus on longer term benefits, toxicity, and broader social effects.
- In the USA and other jurisdictions regulatory authorities need to “re-schedule” cannabis away from the most restrictive designation, recognizing that harm potential is modest, and there are medical benefits. This will facilitate medical research. Example: CBD, which is non psychoactive, is still Schedule 1 and practically unavailable for broader medical research
- In the USA the Federal Government needs to empower States to license producers for medical research to make available a diversity of products in a timely manner.
- If cannabis is to be used as a medicine, it needs to be capable of physician prescription, in accordance with agreed protocols, and subject to availability from trusted sources that confirm potency and purity, and regulated dispensing [eg., pharmacies; regulated dispensaries].
Examples of future research directions on medicinal cannabis

- Studies to address how patient diversity affects treatment response and vulnerability to adverse effects
  - Sex; Age; prior experience with cannabis; co-occurring conditions eg., psychiatric; non cannabis substance disorders; medical, eg., heart disease; liver disease

- Studies on differential effectiveness, adverse effects, of various delivery systems
  - eg., smoked; other inhalational; oral; transdermal; oral-mucosal; suppositories

- Studies on specific cannabinoids
  - eg., THC, CBD, their combination. Other cannabinoids and terpenes?

- Studies on synergistic or sparing effects
  - Reduce or replace opioids, benzodiazepines, or other medications?

- Studies on dosing:
  - eg., are therapeutic [such as analgesic] effects gained at lower doses than psychoactive? Effects of cannabinoid combinations
Current CMCR-Associated Studies

Clinical Trials

- Neuropathic low back pain (Wilsey/Marcotte, NIH)
- Autism (Trauner, Noorda Foundation)
- Essential tremor (Nahab, Essential Tremor Foundation/Tilray)
- Early Psychosis (Cadenhead, Krupp Family Foundation)
- Anorexia Nervosa (Gray/Kaye, UCSD Eating Disorders Clinic)

Observational/acute administration mechanistic studies

- HIV neuropathic pain (Henry, NIH)
- Bipolar disorder (Perry/Young, NIH)

Public Safety

- Cannabis-impaired driving (Marcotte, State of California)
Marijuana as Medicine: Can We See Past the Smoke?

Thank you!

Igor Grant, M.D.
Director

J. Hampton Atkinson, MD & Tom Marcotte, PhD, Co-Directors
Barth Wilsey, MD, Ron Ellis, MD, PhD, Mark Wallace, MD, Robert Fitzgerald, PhD, Investigators; Ben Gouaux and Jennifer Marquie Beck, Senior Staff

www.cmcr.ucsd.edu